Navigation Links
Pharmaceutical Litigation Partner James Stronski Joins Crowell & Moring

WASHINGTON, May 4, 2011 /PRNewswire-USNewswire/ -- Crowell & Moring LLP is pleased to announce the addition of partner James K. Stronski to the firm's Intellectual Property Group. Based in the New York office, Stronski is an intellectual property litigator with extensive experience handling cases involving the so-called "Hatch-Waxman" Amendments to the Federal Food Drug & Cosmetic Act, as well as patent, trade secret, trademark, copyrights, and unfair competition matters. Stronski will be joined by counsel Chiemi D. Suzuki. They join the firm from Frommer Lawrence & Haug LLP.

"Jim has significant first-chair patent litigation experience, having successfully handled a variety of bench and jury trials. He is the perfect complement to our New York office and our growing pharmaceutical litigation and life sciences practice. Jim's versatility and experience in handling high-stakes matters is a tremendous asset to our clients," said Mark Supko, chair of the firm's Intellectual Property Group.

Stronski has been litigating cases primarily in federal courts nationwide for over 20 years. He focuses his practice on the representation of generic pharmaceutical companies in patent litigation related to "Hatch-Waxman" matters. These particular cases involve challenges to pharmaceutical patents by companies wanting to introduce generic versions of patented drugs. Stronski has first chaired trials, evidentiary preliminary injunction and Markman hearings, and has argued before the Federal Circuit.  

With considerable experience in both bench and jury trials, preliminary injunction motions and appellate practice, he has represented clients in a wide range of industries including pharmaceuticals, the internet, consumer products, plastics, high-tech composites, and semiconductor manufacturing equipment. He also has first chaired cases, including through trial, before the Trademark Trial and Appeal Board (TTAB), and advises clients on trademark infringement and clearance issues.

"Crowell & Moring is a premier litigation firm that has built a large, first-class Intellectual Property Group, serving the needs of clients internationally. I am looking forward to being part of the firm and expanding its pharmaceutical patent litigation practice. Beyond the strength of Crowell & Moring's practices, I was attracted to the firm because it has been at the forefront in using alternative fee arrangements, or value based billing, that takes a creative 'risk sharing' attitude, utilizing fee arrangements that I believe may  better align the firm's interests with our clients," said Stronski.

Stronski received his B.A. from Dartmouth College and his J.D. from Fordham Law School. After graduation from Fordham, Stronski completed a two-year clerkship for the Honorable Shirley W. Kram of the U.S. District Court for the Southern District of New York.

Suzuki, a New York-based counsel in the firm's Intellectual Property Group, focuses her practice on patent litigation, primarily related to pharmaceutical litigation under the Hatch-Waxman Act. Prior to private practice, Suzuki worked in technology transfer at the Office of Industrial Liaison at Mount Sinai School of Medicine. She received her B.A. from Bryn Mawr College, M.A. in Biotechnology from Columbia University, and her J.D. from University of California, Hastings College of Law.

Crowell & Moring LLP is an international law firm with nearly 500 lawyers representing clients in litigation and arbitration, regulatory, and transactional matters. The firm is internationally recognized for its representation of Fortune 500 companies in high-stakes litigation, as well as its ongoing commitment to pro bono service and diversity. The firm has offices in Washington, DC, New York, Los Angeles, San Francisco, Orange County, Anchorage, London, and Brussels. Visit Crowell & Moring online at

Contact:   Jessica O'Neil
(202) 508-8750

SOURCE Crowell & Moring LLP
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
2. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
5. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
6. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
7. ( Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
8. Par Pharmaceutical Begins Shipment of Additional Dosage Strength of Generic TOPROL-XL(R)
9. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
10. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
11. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
Post Your Comments:
(Date:11/25/2015)... WILMINGTON, N.C. , Nov. 25, 2015 /PRNewswire/ ... announces the planned investment of at least $15.8 ... in Wilmington, NC . The ... services capacity to meet the growing demands of ... Wilmington site expansion will provide up ...
(Date:11/25/2015)... , Nov. 25, 2015 Allergan plc (NYSE: ... agreement with the New York State ... of the Sherman Act, and other statutes with the Attorney ... February 2014, to cease marketing and selling the now generic ... settlement, Allergan admits no liability, has released its counterclaims against ...
(Date:11/25/2015)... USP 800 applies to all healthcare ... pharmacy technicians, nurses, physicians, physician assistants, home healthcare ... covers all entities which store, prepare, transport, or ... institutions, patient treatment clinics, physicians, practice facilities, and ... --> What is the purpose of USP ...
Breaking Medicine Technology:
(Date:11/26/2015)... ... November 26, 2015 , ... Somu Sivaramakrishnan announced today ... owner, Somu now offers travelers, value and care based Travel Services, including exclusive ... as well as, cabin upgrades and special amenities such as, shore excursions, discounted ...
(Date:11/26/2015)... , ... November 26, 2015 , ... ... set of retro-fused, self-animating trailer titles with ProTrailer: Vintage. This newly styled ProTrailer ... classically-influenced trailer titles work with any font, giving users limitless opportunities to stylize ...
(Date:11/25/2015)... ... 2015 , ... The holiday season is jam-packed with family ... of attendees is of the utmost importance. Whether you are cooking at home ... recipes a try this holiday season. , Turkey Croquettes ,     Ingredients: ...
(Date:11/25/2015)... ... November 26, 2015 , ... Ministers, senior ... (EU), ANDI Pan African Centres of Excellence, and public R&D institutions, civil societies ... the opening of the 5th African Network for Drugs and Diagnostics Innovation, ANDI, ...
(Date:11/25/2015)... ... November 25, 2015 , ... Dental professionals who would like ... , are invited to attend Dr. Mark Iacobelli’s Advanced Implant Mentoring (AIM) CE course. ... OH. , As the co-founders of Advanced Implant Mentoring (AIM), Dr. Iacobelli and ...
Breaking Medicine News(10 mins):